Tourmaline Bio Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Tourmaline Bio Inc in the second quarter 2025?
Tourmaline Bio Inc recorded a cumulative net loss of $-88 million during 12 months ending in the second quarter 2025, resulting in a negative return on equity (ROE) of -30.5%.

Within the Biotechnology & Pharmaceuticals industry 28 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2025 from 2697 to 2716.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter
Y / Y Equity Change	-23.38 %	-20.97 %	46.34 %	-	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-88	-83	-73	-49	-34
Return On Equity (TTM)	-30.5 %	-26.75 %	-22.29 %	-16.04 %	-16.12 %
TRML's Total Ranking	# 2716	# 2697	# 2318	# 2407	# 2158
Equity (TTM) in Millions	259	280	300	321	338
Seq. Equity Change	-7.39 %	-6.73 %	-6.55 %	-5.09 %	-4.48 %
Seq. Net Income Change	-	-	-	-	-

Back to TRML Management Effectiveness >> TRML's 5 Years Annual ROE >> Compare TRML ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 29
Sector	# 291
Overall	# 2716

Return On Equity Statistics
High	Average	Low
-13.72 %	-28.03 %	-43.66 %
(Jun 30 2024)		(Jun 30 2023)

TRML Annual Return On Equity	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	300	205	180	243	0
Y / Y Equity Change	46.34 %	13.88 %	-25.85 %	-	-
Net Income in Millions	-73	-42	-74	-48	0
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-24.4 %	-20.54 %	-41.04 %	-19.7 %	-

Back to TRML Management Effectiveness >> TRML's 5 Years Annual ROE >> Compare TRML ROE to its Competitors

More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
TRML's' Return on Equity at Yahoo Finance
TRML's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for TRML's Competitors
Subscribers only: Roe for Tourmaline Bio Inc 's Suppliers
Subscribers only: Return On Equity for TRML's Customers

Companies with similar Return On Equity at Jun 30 2025, within Healthcare Sector

ROE

Date modified: 2026-09-08T22:38:36+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.